Literature DB >> 9447909

Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

M H Nguyen1, C J Clancy, Y C Yu, A S Lewin.   

Abstract

The potential role of azithromycin in combination with amphotericin B against 25 clinical isolates of Aspergillus was assessed. The MIC of amphotericin B was 1 microg/ml for 44% of the isolates, 0.5 microg/ml for 48%, and 0.25 microg/ml for 8%. All isolates were resistant to azithromycin. Synergism, defined as a > or = twofold reduction in the MIC of both drugs upon combination, was demonstrated between amphotericin B and azithromycin for all 25 isolates. To prove that azithromycin exerts its antifungal effect by inhibiting protein synthesis, we studied [35S]-methionine incorporation into protein in one Aspergillus isolate. Neither amphotericin B at 0.125 microg/ml (fourfold below its MIC) nor azithromycin at 16 microg/ml (> or = 16-fold below its MIC) had any effect on protein synthesis when tested alone. Upon combination, however, a 68% inhibition in protein synthesis was evident by the inhibition of [35S]-methionine incorporation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447909     DOI: 10.1007/bf01700417

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin.

Authors:  M A Cooper; K Nye; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

2.  Azithromycin concentrations in sinus fluid and mucosa after oral administration.

Authors:  P Karma; J Pukander; M Penttilä
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  The biogenesis of mitochondria, VI. Biochemical basis of the resistance of Saccharomyces cerevisiae toward antibiotics which specifically inhibit mitochondrial protein synthesis.

Authors:  A W Linnane; A J Lamb; C Christodoulou; H B Lukins
Journal:  Proc Natl Acad Sci U S A       Date:  1968-04       Impact factor: 11.205

4.  Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.

Authors:  C J Beckers; D S Roos; R G Donald; B J Luft; J C Schwab; Y Cao; K A Joiner
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

5.  Distribution of orally administered azithromycin in various blood compartments.

Authors:  A Wildfeuer; H Laufen; T Zimmermann
Journal:  Int J Clin Pharmacol Ther       Date:  1994-07       Impact factor: 1.366

6.  Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo.

Authors:  S L Andersen; A Ager; P McGreevy; B G Schuster; D Wesche; R Kuschner; C Ohrt; W Ellis; R Rossan; J Berman
Journal:  Am J Trop Med Hyg       Date:  1995-02       Impact factor: 2.345

7.  Preferential concentration of azithromycin in an infected mouse thigh model.

Authors:  J A Retsema; J M Bergeron; D Girard; W B Milisen; A E Girard
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B.

Authors:  M A Lew; K M Beckett; M J Levin
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

9.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.

Authors:  M H Nguyen; F Barchiesi; D A McGough; V L Yu; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  6 in total

1.  In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum.

Authors:  Francielli P K Jesus; Laerte Ferreiro; Érico S Loreto; Maiara B Pilotto; Aline Ludwig; Karine Bizzi; Juliana S M Tondolo; Régis A Zanette; Sydney H Alves; Janio M Santurio
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

Review 2.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  In vitro susceptibility of Pythium insidiosum to macrolides and tetracycline antibiotics.

Authors:  Erico Silva Loreto; Débora Alves Nunes Mario; Laura Bedin Denardi; Sydney Hartz Alves; Janio Morais Santurio
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B.

Authors:  C J Clancy; Y C Yu; A Lewin; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 6.  Drug repurposing strategies in the development of potential antifungal agents.

Authors:  Qian Zhang; Fangyan Liu; Meng Zeng; Yingyu Mao; Zhangyong Song
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-21       Impact factor: 4.813

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.